1. Medtech Insight
  2. >>Business

Premom Fertility App Faces Wrongful Data-Sharing Suit

 
• By Elizabeth Orr

The app allegedly shared sensitive customer information with three China-based data analysis and collection firms.

Screens from the Premom fertility app, which is facing a lawsuit for sharing customer data.
Screens from the Premom fertility app, which is facing a lawsuit alleging it shared customer data • Source: Easy Healthcare

The company behind fertility app Premom is facing a class action suit in Illinois federal court that claims it shared user information with at least three overseas entities, violating customer privacy as well as the app’s terms of use.

The lawsuit, Doe v. Easy Healthcare Corp., was filed in the US District Court for the Northeastern District of Illinois, Eastern Division on 21 January by lead attorney Brendan Donelon...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Medtech Insight

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.

FDLI: Clinical Labs Face Uncertainty After Texas Court’s LDT Ruling

 
• By Elizabeth Orr

A Texas court's decision against US FDA regulation of lab-developed tests (LDTs) has introduced new uncertainties for clinical labs. Industry stakeholders are now worried about potential future regulations while also managing existing compliance requirements. Recent conference discussions underscored the complexities of FDA oversight.